Eiger BioPharmaceuticals (EIGR) Stock Highlights

8.5 | +0%

2024-09-19 07:13:30

Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Statistics

Range Today

8.5 8.5

Volume Today 0

Range 1 Year

0.21 16

Volume 1 Year 24.11M

Range 3 Year

0.21 16

Volume 3 Year 291.77M

Range 10 Year

0.21 423.75

Volume 10 Year 555.52M

Highlights

Market Capitalization 2.55M (micro)

Floating Shares 1.27M

Current Price 8.5

Price To Earnings -0.03

Price To Revenue 0.27

Earnings Per Share -58.5

Payout Ratio 0%

Performance

Latest 0%

1 Month -29.64%

3 Months +155.26%

6 Months +64.73%

1 Year +2025%

3 Years +20.74%

5 Years -28.51%

10 Years -94.58%

Benchmarks

Market Capitalization

347 / 368

Gross Profits

98 / 278

Total Revenue

171 / 300

Total Rank

114 / 368

Free Cashflow

222 / 352

Performance 5 years

170 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.